2018 American Transplant Congress
Assessment of Peak Levels and Metabolism Rates in African American (AA) and Non-AA Kidney Transplant Recipients (KTR) on Immediate-Release Tacrolimus (IR-tac)
Trough-to-daily dose (C/D) ratio has been used as a simple method for evaluation of IR-tac metabolism rate. Recent studies have shown that fast metabolizers defined…2018 American Transplant Congress
Once Daily CNI Administration Based on Pharmacodynamic Analysis for Preventing Viral Infection
BackgroundInfectious complications under immunosuppressive therapy are inevitable problems. Viral infection (include reactivation) occurs at a certain frequency even if immunosuppressive agents are totally adjusted by…2018 American Transplant Congress
Development of Optimal Simplified Equation for Estimation of Mycophenolic Acid Exposure Following Enteric-Coated Mycophenolate Sodium Administration in Chinese Renal Transplant Recipients
MyERA Study Group, Hangzhou, China.
Background: Limited sampling strategies (LSS) aids in overcoming the complexity of extensive PK sampling and supporting the calculation of mycophenolic acid (MPA) exposure. This study…2018 American Transplant Congress
Conversion from Twice Daily Immediate Release Tacrolimus to Once Daily Extended Release Tacrolimus (LCP-Tacro) in High Risk Kidney Transplant Recipients
Extended release once daily tacrolimus (LCP-Tacro) has demonstrated non inferiority to immediate release twice daily tacrolimus (IR-Tac) in kidney transplantation. These data are limited by…2018 American Transplant Congress
Pharmacokinetics of Mycophenolic Acid Following Enteric-Coated Mycophenolate Sodium Administration in Chinese Renal Transplant Recipients
MyERA Study Group, Hangzhou, China.
Background: Mycophenolic acid (MPA), active component of mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS), is the most commonly used immunosuppressant in renal transplant recipients…2018 American Transplant Congress
A Six-Month, Prospective, Single-Center, Pilot Study to Determine the Pharmacokinetics and Effectiveness of Immunosuppressant Regimens in Liver Transplantation Patients Receiving Twice-Daily Tacrolimus and Everolimus (TAC + EVR BID) Regimen Converted to Once-Daily Tacrolimus and Everolimus (TAC + EVR QD) Regimen – A Priliminary Report
Adherence to immunosuppressant regimen is crucial for graft survival and usually inversely related to the dose frequency. Similar efficacy and safety profile has been approved…2018 American Transplant Congress
Evaluation of Clinical and Safety Outcomes Following Uncontrolled Tacrolimus Conversion in Adult Transplant Recipients
Background: Long-term studies with control groups are required to assess tacrolimus (TAC) conversion. The purpose of this study was to compare clinical and safety outcomes…2018 American Transplant Congress
Tacrolimus Metabolism in Subjects with Potentially Absent CYP3A Activity
Purpose: Tacrolimus (TAC) is a well-known cytochrome P450 (CYP) 3A4 and 3A5 substrate. Common single nucleotide polymorphisms (SNPs) in these genes are significantly related to…2018 American Transplant Congress
Tacrolimus Pharmacokinetics (PK) at Low, Medium, and High Trough Levels in Patients Converted from Twice-Daily Immediate-Release Tacrolimus (TacBID) to Once-Daily Extended-Release Tacrolimus (LCPT)
LCPT (Envarsus XR®) is a once-daily, extended-release formulation of tacrolimus which has demonstrated greater bioavailability and a smoother PK profile compared to TacBID. This post-hoc…2017 American Transplant Congress
Tacrolimus Intra-Patient Variability Determined from Daily Trough Levels in Adherent Kidney and Liver Transplant Recipients.
Drugs are classified as highly variable when intra-patient coefficient of variation (CV%) is > 30%. Tacrolimus (TAC) is characterized as highly variable often without supporting…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 12
- Next Page »